Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study of E6005 in Japanese Patients With Atopic Dermatitis
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 40
- Registration Number
- NCT01179880
A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 80
- Registration Number
- NCT01165424
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1547
- Registration Number
- NCT01154036
Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)
Phase 3
Completed
- Conditions
- Infertility
- Interventions
- Biological: Corifollitropin alfaBiological: recFSH (follitropin beta)
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 307
- Registration Number
- NCT01146418
Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)
Phase 3
Completed
- Conditions
- Infertility
- Interventions
- Biological: SCH 900962 / Corifollitropin alfa / Org 36286Biological: RecFSH / follitropin betaDrug: Placebo for SCH 900962Drug: Placebo for recFSH
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1424
- Registration Number
- NCT01144416
Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 201
- Registration Number
- NCT01142596
Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)
Completed
- Conditions
- Respiratory Syncytial Virus Bronchiolitis
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 343
- Registration Number
- NCT01140048
Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 333
- Registration Number
- NCT01135134
A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
Phase 2
Completed
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2010-04-12
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 8
- Registration Number
- NCT01101464
6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 532
- Registration Number
- NCT01098110